Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | POLG | P54098 | 1/20 | 0.39 |
| ▸ | DCK | P27707 | 12/20 | 0.35 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25431915 | 1.00 | ALB (0.50) | ALBPOLGDCKDNMT1ADRB1 | |
| SCHEMBL26269257 | 0.93 | ALB (0.54) | ALBPOLGDCKDNMT1ADRB1 | |
| SCHEMBL25399071 | 0.90 | ALB (0.51) | ALBPOLGDCKDNMT1ADRB1 | |
| SCHEMBL26794133 | 0.89 | ALB (0.50) | ALBPOLGDCKDNMT1ADRB1 | |
| SCHEMBL26269371 | 0.89 | ALB (0.50) | ALBPOLGDCKDNMT1 | |
| SCHEMBL17533848 | 0.89 | ALB (0.50) | ALBPOLGDCKDNMT1ADRB1 | |
| SCHEMBL25398805 | 0.89 | ALB (0.50) | ALBPOLGDCKDNMT1ADRB1 | |
| SCHEMBL26269258 | 0.89 | ALB (0.50) | ALBPOLGDCKDNMT1 | |
| SCHEMBL32670408 | 0.89 | ALB (0.47) | ALBPOLGDCKDNMT1 | |
| SCHEMBL31653144 | 0.89 | ALB (0.47) | ALBPOLGDCKDNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4493573-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | Rome Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12187758-B2 | Compounds and methods for treating disease | ROME THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023192499-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | ALB 4486/4885POLG 40/4885DCK 146/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | ALB 4486/4885POLG 40/4885DCK 146/4885 |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | ALB 4851/4885POLG 82/4885DCK 50/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | ALB 4486/4885POLG 40/4885DCK 146/4885 |
| US-12187758-B2 | Compounds and methods for treating disease | EHMT1, POLRMT, RNASE1 | ALB 4486/4885POLG 40/4885DCK 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.